Sleep-disordered breathing is a risk factor for dementia in women

Adding to the damage list associated with sleep-disordered breathing, a study just published in JAMA (The Journal of the American Medical Association) offers evidence that sleep apneas and hypopneas can contribute to serious cognitive impairment. This is not surprising considering the importance of oxygen for brain health. The authors state:

“Sleep-disordered breathing (characterized by recurrent arousals from sleep and intermittent hypoxemia) is common among older adults. Cross-sectional studies have linked sleep-disordered breathing to poor cognition…”

So they designed their study to…

“…determine the prospective relationship between sleep-disordered breathing and cognitive impairment and to investigate potential mechanisms of this association.”

Defining sleep-disordered breathing as an apnea-hypopnea index of 15 or more events per hour of sleep, they examined polysomnography (‘sleep study’) data for 298 women without dementia collected between January 2002 and April 2004. They then used data collected  between November 2006 and September 2008 to correlate hypoxia, sleep fragmentation, and sleep duration with cognitive status (normal, dementia, or mild cognitive impairment). What did the data reveal?

“Compared with the 193 women without sleep-disordered breathing, the 105 women (35.2%) with sleep-disordered breathing were more likely to develop mild cognitive impairment or dementia (31.1% vs 44.8%). Elevated oxygen desaturation index (≥15 events/hour) and high percentage of sleep time (>7%) in apnea or hypopnea (both measures of disordered breathing) were associated with risk of developing mild cognitive impairment or dementia (AOR, 1.71 and AOR, 2.04, respectively).”

In other words, the higher strata of sleep-disordered breathing doubled the risk for dementia. Interestingly…

“Measures of sleep fragmentation (arousal index and wake after sleep onset) or sleep duration (total sleep time) were not associated with risk of cognitive impairment.”

Clinicians need to bear in mind the serious metabolic, cardiovascular and cognitive penalties of sleep-disordered breathing and question patients about tell-tale signs such has heavy snoring and daytime somnolence. The authors conclude:

“Among older women, those with sleep-disordered breathing compared with those without sleep-disordered breathing had an increased risk of developing cognitive impairment.”

This study cohort was all female subjects, but I can think of no reason why the same consideration does not apply to male patients.

 

Omega-3 fatty acids and depression in adolescents

Imbalances or deficiencies in essential fatty acids which are critical brain components can contribute to depression and neurological disorders. A study just published online in the journal Acta Pædiatrica delineates the decisive difference they make in adolescents. The authors set out to…

“…study the relationship between polyunsaturated fatty acids (PUFA) status and depression in adolescents with eating disorders (ED) and weight loss.”

They measured essential fatty acids (FA) in the red blood cell membranes of 217 adolescents with eating disorders. As the clinicians reading this know, erythrocyte fatty acids also reflect the fatty acid status of the brain. The study subjects were also examined for depression by clinical interviews and psychological self-report instruments. A clear-cut picture emerged from the data:

“Adolescents with ED and depression did not differ from those with ED only in terms of age, BMI, weight loss and duration of disease. In their FA profile depressed adolescents had lower proportions of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA), the end products of the ω3 PUFA series. The ratio of long chain (>18 carbons) ω6/ω3 PUFA was therefore higher in depressed adolescents. Indices of desaturase activites did not differ between depressed and not depressed adolescents.”

In other words, the only difference among the factors examined in this study between the adolescents with and without depression  was their essential fatty acid status. Thus the authors conclude:

Low ω3 status is related to depression in adolescents with ED. This cannot be explained by differences in weight (loss) and duration of disease, nor by differences in PUFA processing by desaturases. Data suggest a lower dietary intake of ω3 PUFA in those with depression. Further investigations should determine whether ω3 PUFA status improves by refeeding only or whether supplementation with PUFA is warranted.”

See also the Parents’ Guide To Brain Health for additional evidence of the role of fatty acids, along with information on the other important aspects.

Childhood head injuries linked to subsequent interpersonal violence

A study just published in the journal Pediatrics documents the association of interpersonal violence in young adulthood with earlier head injury. The authors state:

“The purpose of this study was to examine differences in interpersonal violence among individuals who reported a head injury compared with those who did not report a head injury.”

They examined 8 years of data for 850 kids in 4 public high schools in a Midwestern city, looking specifically at the years from mid-adolescence to the transition into young adulthood, correlating levels of interpersonal violence with reports of head injury. Multivariate regression analyses, controlling for variables such as race, gender, and previous violence, as well as risk behaviors such as alcohol and marijuana use, were used to determine whether head injury was associated with subsequent violent behavior. What did the data show?

Participants who had ever experienced a head injury before young adulthood reported more interpersonal violence in young adulthood than participants who had never had a head injury. In multivariate analyses, respondents who had a head injury in the past year reported more subsequent interpersonal violence than respondents who had not had a head injury.”

As noted in our Parents’ Guide To Brain Health even a mild traumatic brain injury can set in motion a cascade of effects that compromise brain function for cognition, impulse control and regulation of emotions. There are remedial measures that can help if the problem is recognized and properly assessed when we keep in mind the authors’ conclusion:

Our findings support other studies that link history of head injury to later interpersonal violence.

Chronic fatigue syndrome and the XMRV virus

There are many ways to fall prey to simplistic linear thinking when desperately seeking solutions to complex problems. Chronic Fatigue Syndrome can be a devastating illness; as attractive as a viral culprit may be to some, there is abundant evidence that attributing this complex condition to a singular cause unrealistically ignores the complexity of CFS and related conditions. A study just published in the Journal of Virology is the most recent ‘nail in the coffin’ for the notion that CFS is caused by the XMRV virus. The authors state:

Chronic fatigue syndrome (CFS) is a multi-system disorder characterized by prolonged and severe fatigue that is not relieved by rest…Recently CFS has been associated with xenotropic murine leukemia virus-related virus (XMRV) as well as other murine leukemia virus (MLV)-related viruses, though not all studies have found these associations.”

They analyzed blood samples from 100 CFS patients and 200 self-reported healthy volunteers using molecular, serological and viral replication assays. Interestingly, they also analyzed samples from patients in the original study that attracted so much media attention when it reported XMRV in CFS. What were the results?

We did not find XMRV or related MLVs, either as viral sequences or infectious virus, nor did we find antibodies to these viruses in any of the patient samples, including those from the original study. We show that at least some of the discrepancy with previous studies is due to the presence of trace amounts of mouse DNA in the Taq polymerase enzymes used in these previous studies.”

Attention to their conclusion may prevent clinicians and CFS sufferers from a fruitless diversion:

Our findings do not support an association between CFS and MLV-related viruses including XMRV and off-label use of antiretrovirals for the treatment of CFS does not seem justified at present.”

This is a thorough and detailed study, but is there any other evidence to support the assertion that we shouldn’t depend on XMRV as a linear viral cause for CFS? A study recently published in the journal Retrovirology also finds no association in cases across the US:

“Here we tested blood specimens from 45 CFS cases and 42 persons without CFS from over 20 states in the United States for both XMRV and MuLV. The CFS patients all had a minimum of 6 months of post-exertional malaise and a high degree of disability, the same key symptoms described in the Lombardi et al. study. Using highly sensitive and generic DNA and RNA PCR tests, and a new Western blot assay employing purified whole XMRV as antigen, we found no evidence of XMRV or MuLV in all 45 CFS cases and in the 42 persons without CFS. Our findings, together with previous negative reports, do not suggest an association of XMRV or MuLV in the majority of CFS cases.”

Additional research published shortly after in the same journal came up with the same negative results for both CFS and prostate cancer in Japan:

“To evaluate the risk of XMRV infection during blood transfusion in Japan, we screened three populations–healthy donors (n = 500), patients with PC (n = 67), and patients with CFS (n = 100)–for antibodies against XMRV proteins in freshly collected blood samples. We also examined blood samples of viral antibody-positive patients with PC and all (both antibody-positive and antibody-negative) patients with CFS for XMRV DNA.”

Their data led them to the following conclusion:

“Our data show no solid evidence of XMRV infection in any of the three populations tested, implying that there is no association between the onset of PC or CFS and XMRV infection in Japan.”

A study recently published in PLoS ONE (Public Library of Science) goes a step further in examining the issue. The authors state:

“The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS.”

In addition to the PCR protocol used in the original study, the authors also assayed the sera of CFS patients for the presence of both the xenotropic virus envelope protein and a serological response to it. What did their data show?

The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.”

Subsequent research also conducted in the UK and published in PLoS examined a highly susceptible cohort of patients for XMRV virus:

We extracted peripheral blood DNA from a cohort of 540 HIV-1-positive patients (approximately 20% of whom have never been on anti-retroviral treatment) and determined the presence of XMRV and related viruses using TaqMan PCR.”

Even for this very vulnerable group XMRV was not proven to be a concern:

In view of these negative findings in this highly susceptible group, we conclude that it is unlikely that XMRV or related viruses are circulating at a significant level, if at all, in HIV-1-positive patients in London or in the general population.

The authors of a study just published in the Annals of Neurology go a step further in investigating whether XMRV could be a causative agent in CFS. Having acknowledged the pre-existing research, they state:

“A useful next step would be to examine cerebrospinal fluid, because in some patients CFS is thought to be a brain disorder. Finding a microbe in the central nervous system would have greater significance than in blood because of the integrity of the blood–brain barrier.”

The brain is at the core of the experience of fatigue; if the virus were to show up anywhere it should be there. What did they find?

We examined cerebrospinal fluid from 43 CFS patients using polymerase chain reaction techniques, but did not find XMRV or multiple other common viruses, suggesting that exploration of other causes or pathogenetic mechanisms is warranted.”

Just because a virus may be found in the body of a patient with CFS or any other condition does not mean that it is a significant causal factor for their complaint. The authors of a paper published in the British Medical Bulletin undertook a survey of…

“…All papers including the wording XMRV were abstracted from the NIH library of medicine database and included in the analysis.”

They make the point that…

“An increasing number of papers now refute the association of XMRV with human disease in humans although there is some evidence of serological reactivity to the virus. While it is unlikely that XMRV is a major cause of either prostate cancer or CFS, it can infect human cells and might yet have a role in human disease.”

But there is a big difference between being present in human cells and being a cause of disease. This is illustrated by a fascinating study published in the Journal of Virology showing that XMRV does not efficiently replicate and spread in human tissue. The authors state:

“To determine whether XMRV can replicate and spread in cultured PBMCs even though it can be inhibited by A3G/A3F, we infected phytohemagglutinin-activated human PBMCs and A3G/A3F-positive and -negative cell lines (CEM and CEM-SS, respectively) with different amounts of XMRV and monitored virus production by using quantitative real-time PCR.”

They summarize their findings by concluding:

“We found that XMRV efficiently replicated in CEM-SS cells and viral production increased by >4,000-fold, but there was only a modest increase in viral production from CEM cells (<14-fold) and a decrease in activated PBMCs, indicating little or no replication and spread of XMRV…Overall, these results suggest that hypermutation of XMRV in human PBMCs constitutes one of the blocks to replication and spread of XMRV.”

Wishing for a single linear cause that will lend itself to the discovery of a ‘magic bullet’ for conditions that are engendered by a multi-causal systemic web of factors is a flaw that has hindered progress in the treatment of chronic disease. In the case of CFS, dysregulation of the brain-immune axis is a core component. This demands that the clinician integrate a panoramic systems view with a nuanced investigation of individual functional elements. There is a world of science to delve into here; research just published in the journal NMR In Biomedicine offers a taste of the brain aspect. The authors in order to:

“…explore brain involvement in chronic fatigue syndrome (CFS), the statistical parametric mapping of brain MR [magnetic resonance] images has been extended to voxel-based regressions against clinical scores.”

The compared MR signal levels in 25 CFS subjects and 25 normal controls, including such clinical scores as fatigue duration, another score based on the 10 most common CFS symptoms, the hospital anxiety and depression scale (HADS) anxiety and depression, and hemodynamic parameters from 24 hour blood pressure monitoring. What did their data show?

“In the midbrain, white matter volume was observed to decrease with increasing fatigue duration. For T1-weighted MR and white matter volume, group × hemodynamic score interactions were detected in the brainstem [strongest in midbrain grey matter (GM)], deep prefrontal white matter (WM), the caudal basal pons and hypothalamus. A strong correlation in CFS between brainstem GM volume and pulse pressure suggested impaired cerebrovascular autoregulation. It can be argued that at least some of these changes could arise from astrocyte dysfunction.”

In other words, there were strong correlations between CFS symptoms and pathological changes in the brain. The authors conclude:

“These results are consistent with an insult to the midbrain at fatigue onset that affects multiple feedback control loops to suppress cerebral motor and cognitive activity and disrupt local CNS homeostasis, including resetting of some elements of the autonomic nervous system (ANS).

How might such neurodegenerative changes come about? A paper published earlier in Autoimmunity Reviews discusses the autoimmune component of CFS:

“The current concept is that CFS pathogenesis is a multifactorial condition. Various studies have sought evidence for a disturbance in immunity in people with CFS. An alteration in cytokine profile, a decreased function of natural killer (NK) cells, a presence of autoantibodies and a reduced responses of T cells to mitogens and other specific antigens have been reported. The observed high level of pro-inflammatory cytokines may explain some of the manifestations such as fatigue and flu-like symptoms and influence NK activity. Abnormal activation of the T lymphocyte subsets and a decrease in antibody-dependent cell-mediated cytotoxicity have been described. An increased number of CD8+ cytotoxic T lymphocytes and CD38 and HLA-DR activation markers have been reported, and a decrease in CD11b expression associated with an increased expression of CD28+ T subsets has been observed.”

The main point: practitioners and patients should not be seduced by the wish for a ‘magic bullet’ treatment of a single linear cause for complex conditions that require a systems biology perspective. In the case of chronic fatigue syndrome, the brain-immune axis comes to the fore, with all its multifaceted considerations for functional assessment and treatment.

Bright light helps non-seasonal major depression in the elderly

More evidence for the profound effects of light therapy is offered in a randomized placebo-controlled trial published recently in the Archives of General Psychiatry that documents the effectiveness of bright light therapy for relieving depression. The authors first observe:

Major depressive disorder (MDD) in elderly individuals is prevalent and debilitating. It is accompanied by circadian rhythm disturbances associated with impaired functioning of the suprachiasmatic nucleus, the biological clock of the brain. Circadian rhythm disturbances are common in the elderly. Suprachiasmatic nucleus stimulation using bright light treatment (BLT) may, therefore, improve mood, sleep, and hormonal rhythms in elderly patients with MDD.”

They went about testing their assumption with a double-blind, placebo-controlled randomized clinical trial of bright light treatment (BLT) with 89 subjects age 60 or above living in the Amsterdam region who suffered from MDD. Treatment consisted of three weeks of 1-hour early-morning BLT (pale blue, approximately 7500 lux) vs placebo (dim red light, approximately 50 lux). They were assessed for the degree of depression at baseline (T0), after 3 weeks of treatment (T1), and 3 weeks after the end of treatment (T2) with the Hamilton Scale for Depression and cortisol and melatonin levels. As for the results:

“Intention-to-treat analysis showed Hamilton Scale for Depression scores to improve with BLT more than placebo from T0 to T1 (7%) and from T0 to T2 (21%). At T1 relative to T0, get-up time after final awakening in the BLT group advanced by 7%, sleep efficiency increased by 2%, and the steepness of the rise in evening melatonin levels increased by 81% compared with the placebo group. At T2 relative to T0, get-up time was still advanced by 3% and the 24-hour urinary free cortisol level was 37% lower compared with the placebo group. The evening salivary cortisol level had decreased by 34% in the BLT group compared with an increase of 7% in the placebo group.”

Remember, this is not seasonal affective disorder (SAD) but non-seasonal major depression. It’s also noteworthy that beneficial effects could still be measured three weeks after the end of treatment. The authors conclude:

In elderly patients with MDD, BLT improved mood, enhanced sleep efficiency, and increased the upslope melatonin level gradient. In addition, BLT produced continuing improvement in mood and an attenuation of cortisol hyperexcretion after discontinuation of treatment.

Persistent gastrointestinal symptoms demand a look at the brain-gut axis

Assuming that gross pathologies, infections and dietary imprudence have been ruled out, persistent gastrointestinal symptoms require an assessment of the brain-gut axis. More than ever before, research is revealing the profound degree to which gastrointestinal function and even tissue integrity depend on brain output. A spate of earlier reports emphasized the abnormal brain response to sensory signals received from the gut, as in a paper published in Gastroenterology Clinics of North America. The author states:

“Functional neuroimaging studies have demonstrated evidence of altered regional brain activation responses during visceral and somatic stimuli in IBS [irritable bowel syndrome]…Altered brain responses in IBS, particularly to visceral stimuli, include activation of regions concerned with attentional processes and response selection, corticolimbic regions concerned with emotional and autonomic responses to stimuli, and subcortical regions receiving cortical projections from the latter and afferent input from the soma [body] and viscera [organs].”

And remarkably…

Altered activations of these regions also may be present [even] in the absence of a noxious visceral stimulus.

A further indication of the relevance of these observations is that…

“Changes in rCBF [regional cerebral blood flow, a metric for brain function] of some of these regions have been associated with treatment response in IBS.”

As in so many other clinical conditions, loss of cortical inhibitory function—the brain’s great task of calming or attenuating incoming signals—is suggested here:

“A plausible hypothesis for the observations from brain imaging studies is that IBS patients demonstrate a compromised activation of pain inhibition circuits including those of the cortico-pontine circuit but increased activation of limbic and paralimbic circuits that may be related to pain facilitation.”

The authors of a study published in the American Journal of Gastroenterology come to a similar conclusion. Importantly, they also note an association with fibromyalgia:

“Symptoms of irritable bowel syndrome (IBS) and fibromyalgia (FM) commonly coexist. We hypothesized that one of the mechanisms underlying this comorbidity is increased activation of brain regions concerned with the processing and modulation of visceral and somatic afferent information, in particular subregions of the anterior cingulate cortex (ACC).”

With their data they were able to discriminate between IBS and IBS + fibromyalgia in the modulation of brain responses to stimuli:

“”Whereas the somatic stimulus was less unpleasant than the visceral stimulus for IBS patients without FM, the somatic and visceral stimuli were equally unpleasant in the IBS + FM group…There was a greater rCBF increase in response to noxious visceral stimuli in IBS patients and to somatic stimuli in IBS + FM patients.”

Thus the authors conclude that exaggerated brain responses to peripheral stimuli play a role in both IBS and FM. In this context ‘cognitive enhancement’ means inhibition failure:

Chronic stimulus-specific enhancement of ACC responses to sensory stimuli in both syndromes may be associated with cognitive enhancement of either visceral (IBS) or somatic (IBS + FM) sensory input and may play a key pathophysiologic role in these chronic pain syndromes.”

Brain control of the immune system in the gut and disturbances in neuroimmune regulation that persist long after an initial insult such as GI infection are discussed in a paper just published in Nature Reviews Gastroenterology & Hepatology. The authors state:

IBS is one of the most common functional gastrointestinal disorders worldwide and is thought to be the result of disturbed neural function along the brain–gut axis…important roles for low-grade inflammation and immunological alterations in the development of symptoms compatible with IBS have become evident.”

As in so many other varied conditions and chronic pain syndromes, disturbance of the regulatory loop between the brain and periphery becomes the cause of chronic symptoms even long after the initial insult has resolved:

“The development of long-standing gastrointestinal symptoms after infectious gastroenteritis and patients with IBD [inflammatory bowel disease] in remission frequently having functional gastrointestinal symptoms support this hypothesis.”

Loss of the barrier function of the lining of the intestine that separates its contents from the surrounding immune tissue—abnormal intestinal permeability—is a key feature of brain-gut neuroimmune dysfunction.

“In addition, studies have demonstrated that IBS may be associated with an activated adaptive immune response. Increased epithelial barrier permeability and an abnormal gut flora might lead to increased activation of the intestinal immune system. Functional and anatomical evidence for abnormal neuroimmune interactions has been found in patients with IBS.

Clinicians and patients alike with experience of complaints associated with intestinal permeability appreciate how vexing a problem this can be to manage. A fascinating paper published in the Journal of Neurotrauma sheds light on the usually overlooked yet critical role of the brain in maintaining and repairing the gut lining. The authors state:

Traumatic brain injury (TBI) can lead to several physiologic complications including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability, which may lead to bacterial translocation, sepsis, and eventually multi-system organ failure.”

They examined animals subject to TBI for expression of the zonulin [ZO-1] and occludin, proteins critical for integrity of the intestinal lining, to determine if they decreased following TBI. They also looked for a subsequent increase in intestinal permeability. What did their data show?

TBI caused a significant increase in intestinal permeability compared to sham animals 6 h after injury. Expression of ZO-1 was decreased by 49% relative to sham animals, whereas expression of occludin was decreased by 73% relative to sham animals.”

This has great clinical significance: brain output is critical for maintenance of the intestinal epithelium. The authors conclude:

An increase in intestinal permeability corresponds with decreased expression of tight junction proteins ZO-1 and occludin following TBI. Expression of intestinal tight junction proteins may be an important factor in gastrointestinal dysfunction following brain injury.”

A paper published in the Journal of Physiology and Pharmacology describes one effect of disturbance of the brain-gut axis as an increase in visceral sensitivity. The authors note:

“Chronic abdominal pain is the most distressing symptom in patients with functional digestive disorders (FDD)…a chronic visceral hyperalgesia, in the absence of detectable organic disease, is implicated…Several lines of evidence suggest a strong modulatory or etiologic role of the central nervous system in the pathophysiology of IBS…These findings were consistent with an IBS model that includes both the exaggerated activation of a vigilance network (dorsolateral PFC) and a failure in pain inhibition network anterior cingulate cortex (ACC).”

They report their findings on using fMRI (functional magnetic resonance imaging) to characterize the areas of the brain activated by rectal distension in healthy volunteers and compared them with the activation patterns in a population of IBS patients. In the latter…

“…we did not observe any neuronal activation in locations activated in healthy volunteers (ACC [anterior cingulate cortex], dorsolateral PFC) while a significant deactivation was observed in the IC [insular cortex] and in the amygdala, a limbic structure with a role to assign emotional significance to a current experience related to anxiety and fear. Brain imaging techniques thus appear as useful tools to characterize normal and abnormal brain processing of visceral pain in patients with FDD.”

Another study published recently in the same journal reported on the brain’s output for stimulating the production of pancreatic digestive enzymes:

Brain is also implicated in the regulation of pancreatic exocrine function. Dorsal vagal complex of the brainstem (DVC) appears the center of long vago-vagal cholinergic entero-pancreatic reflex.”

It is of great practical importance for clinicians to bear in mind that the immune system is part of the brain-gut axis, and that there is a bi-directional communication between the enteric nervous and immune systems in the gut and the brain. Naturally brain-gut regulation is also influenced by emotion and cognition. A review just published in the journal Brain, Behavior and Immunity offers an aerial perspective:

“The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity.”

Regarding the role of the immune system:

“At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia.”

The authors also assert that the higher level of “top-down” regulation must be considered:

“…recent advances in research on the pathophysiology of visceral hyperalgesia…support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered…Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions.”

And, of course, it’s a ‘two-way street’—disturbed immune and neural signalling go the other way too:

“At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms.”

The authors of a paper published in Gastroentérologie Clinique et Biologique also comment on this two-way channel:

There is a bidirectional relation between the central nervous system and the digestive tract, i.e., the brain-gut axis. Numerous data argue for a dysfunction of the brain-gut axis in the pathophysiology of irritable bowel syndrome (IBS). Visceral hypersensitivity is a marker of IBS as well as of an abnormality of the brain-gut axis. This visceral hypersensitivity is peripheral and/or central in origin and may be the consequence of digestive inflammation or an anomaly of the nociceptive [pain-sensing] message treatment at the spinal and/or supraspinal level.”

Importantly, brain-gut axis dysregulation is also expressed through the autonomic (sympathetic and parasympathetic) nervous system…

Disturbances of the autonomic nervous system are observed in IBS as a consequence of brain-gut axis dysfunction.”

A study published in the journal Neurology offers additional evidence that the brain is a key component of chronic gastrointestinal and other chronic pain disorders . The authors recognize the link between this and fibromyalgia:

“Abnormal cortical pain responses in patients with fibromyalgia and conversion disorder raise the possibility of a neurobiologic basis underlying so-called “functional” chronic pain.”

They used fMRI (functional MRI) to examine the brains of healthy subjects and those with IBS while stimulating with rectal distension. Their experiences with pain or urging were correlated with the fMRI data. There was a clear difference between the IBS and normal subjects:

“In IBS, abnormal responses associated with rectal-evoked sensations were identified in five brain regions. In primary sensory cortex, there were urge-related responses in the IBS but not control group. In the medial thalamus and hippocampus, there were pain-related responses in the IBS but not control group.”

The authors concluded:

“Percept-related fMRI revealed abnormal urge- and pain-related forebrain activity during rectal distension in patients with irritable bowel syndrome (IBS)…abnormal brain responses in IBS may reflect the sensory symptoms of rectal pain and hypersensitivity, visceromotor dysfunction, and abnormal interoceptive processing.”

The authors of another paper published in Gastroentérologie Clinique et Biologique came to similar conclusions regarding the interactions of the brain, immune system and higher functions. [For lay readers of this post: the enteric nervous system (the 'brain in the gut') is part of the autonomic nervous system that regulates all visceral functions including those in the gut].

“Hypersensitivity is due either to an afferent neurons dysfunction at the enteric nervous system level, either to an abnormal brain-gut axis processing of sensory or nociceptive inputs arising from the gut, at the spinal or supraspinal level. Disturbances of the autonomic nervous system occur in IBS as a consequence of this brain-gut axis dysfunction.”

Moreover…

“Neurological abnormalities may be triggered by inflammation, mast cell [a type of immune cell] dysfunction or increased intestinal permeability while the neuro-immune consequences of stress (mainly chronic) play a major role…”

And of course…

“The role of emotions and mood disturbances cannot be omitted in the interpretation the central processing of digestive sensory inputs. Neurosciences, in particular brain imaging techniques, have contributed to this better understanding of irritable bowel syndrome pathophysiology.”

A study published in The Journal of Neuroscience demonstrates how anticipation can affect brain regions that function to regulate sensory signals coming from the gut:

“Cognitive factors such as fear of pain and symptom-related anxiety play an important role in chronic pain states. The current study sought to characterize abnormalities in preparatory brain response before aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possible relationship to the consequences of distention.”

They too used brain fMRI to examine the differences in response to rectal distention between IBS patients and healthy controls. Their data showed marked differences in the ability to activate brain areas responsible for anticipatory calming and for inhibition of sensory signals coming from the intestines during distention:

“During cued anticipation of distention, activity decreased in the insula, supragenual anterior cingulate cortex (sACC), amygdala, and dorsal brainstem (DBS) of controls. IBS patients showed less anticipatory inactivation…During subsequent distention, both groups showed activity increases…[relevant brain areas]…The increases were more extensive in patients, producing significant group differences in dorsal ACC and DBS.”

The authors conclude that diminished inhibitory function may result in a heightened sensitivity to sensations from the gut:

“Deficits in preparatory inhibition of DBS, including the locus ceruleus complex and parabrachial nuclei, may interfere with descending corticolimbic inhibition and contribute to enhanced brain responsiveness and perceptual sensitivity to visceral stimuli in IBS.”

A subsequent study published in the journal GUT, An International Journal of Gastroenterology and Hepatology specifically examines the effect of anxiety and depression on the central nervous system processing of visceral stimuli. The authors set out to…

“…address the role of anxiety and depression symptoms in altered pain processing in irritable bowel syndrome (IBS).

They too used fMRI to compare patients with IBS to normal controls for the experience of pain or discomfort in correlation with brain activation. As before the data told an unambiguous story:

“Anxiety symptoms in IBS were significantly associated with pain-induced activation of the anterior midcingulate cortex and pregenual anterior cingulate cortex. Depression scores correlated with activation of the prefrontal cortex (PFC) and cerebellar areas within IBS. Group comparisons with the two-sample t test revealed significant activation in the IBS versus controls contrast in the anterior insular cortex and PFC.”

This is certainly not earth-shaking news, but it does objectively show how anxiety and depression can affect brain function in such a way that visceral stimuli are permitted to bombard the senses abnormally:

Altered central processing of visceral stimuli in IBS is at least in part mediated by symptoms of anxiety and depression, which may modulate the affective–motivational aspects of the pain response.

The authors of a review published in Psychopharmacology document how the stress of maternal separation can cause brain-gut axis dysfunction. Referring to early life stress they state…

“…stress during this critical period also induces alterations in many systems throughout the body…Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is thought to involve a dysfunctional interaction between the brain and the gut. Essential aspects of the brain–gut axis include spinal pathways, the hypothalamic pituitary adrenal axis, the immune system, as well as the enteric microbiota. Accumulating evidence suggest that stress, especially in early life, is a predisposing factor to IBS.”

Having reviewed the relevant data, they…

“…describe the components of the brain–gut axis individually and how they are altered by maternal separation. The separated phenotype is characterised by alterations of the intestinal barrier function, altered balance in enteric microflora, exaggerated stress response and visceral hypersensitivity…”

What are practitioners to make of all this when endeavoring to help someone with a chronic gastrointestinal complaint? Having investigated for gross pathologies, infections, and food allergies or intolerances, the science indicates that we must accept the role of the brain-gut axis in enteric immune function, maintaining the gut epithelium, and regulating digestive function and sensory phenomena. The brain-gut axis, like all sentient biological entities, is an emergent system. A quote from David Brooks writing in the New York Times offers a working definition:

Emergent systems are ones in which many different elements interact. The pattern of interaction then produces a new element that is greater than the sum of the parts, which then exercises a top-down influence on the constituent elements…Emergent systems are bottom-up and top-down simultaneously. They have to be studied differently, as wholes and as nested networks of relationships.”

Realistically, case management of brain-gut axis disorders requires attending to the multiple factors that influence brain function (a brief overview is available as the Parents’ Guide To Brain Health; it pertains equally to adults). Bottom-up and top-down simultaneously in this case implies that the physiological capacity of the brain to inhibit and stimulate appropriately, and cognition/emotion, are given equal treatment with the condition of the gut microbial ecology and factors that may promote a local inflammatory response. A full treatment of this topic is at least a weighty volume, but there are some recent reports of practical clinical significance on centrally acting therapies for the brain-gut axis worth mentioning in this context. The authors of a paper published in Gastroenterology Clinics of North America state:

“Irritable bowel syndrome (IBS) and other functional gastrointestinal (GI) disorders typically defy traditional diagnostic methods based on structural abnormalities, and has led to the emergence of the discipline of neurogastroenterology or the study of the “brain-gut axis,” which is based on dysregulation of neuroenteric pathways as a key pathophysiological feature of IBS. Centrally acting treatments can influence these pathways and improve the clinical manifestations of pain and bowel dysfunction associated with this disorder. To successfully implement these treatment strategies, it is important to recognize their dual effects on brain and gut…

In this respect we can appreciate the key role of the autonomic nervous system since there are practical ways to objectively evaluate ANS function in an office-based practice (heart rate variability analysis) and non-invasive therapies that modulate the brain and ANS through sensory-based peripheral modalities (all kinds of peripheral stimuli applied to elicit a corrective central response). The author of a paper published recently in La revue de médecine interne notes:

“Our digestive tract has an autonomous functioning but also has a bidirectional relation with our brain known as brain-gut interactions. This communication is mediated by the autonomous nervous system, i.e., the sympathetic and parasympathetic nervous systems, with a mixed afferent and efferent component, and the circumventricular organs located outside the blood-brain barrier. The vagus nerve, known as the principal component of the parasympathetic nervous system…has also anti-inflammatory properties both through the hypothalamic pituitary adrenal axis (through its afferents) and the cholinergic anti-inflammatory pathway (through its efferents). The sympathetic nervous system has a classical antagonist effect on the parasympathetic nervous system at the origin of an equilibrated sympathovagal balance in normal conditions.”

This invites another look at an earlier post documenting the anti-inflammatory role of the parasympathetic nervous system and the use of heart rate variability analysis to objectively evaluate its function. The ANS is the neural communicating channel between the brain and the gut, offering therapeutic access to both…

“The brain is able to integrate inputs coming from the digestive tract inside a central autonomic network organized around the hypothalamus, limbic system and cerebral cortex (insula, prefrontal, cingulate) and in return to modify the autonomic nervous system and the hypothalamic pituitary adrenal axis in the frame of physiological loops. A dysfunction of these brain-gut interactions, favoured by stress, is most likely involved in the pathophysiology of digestive diseases such as irritable bowel syndrome or even inflammatory bowel diseases. A better knowledge of these brain-gut interactions has therapeutic implications in the domain of pharmacology, neurophysiology, behavioural and cognitive management.”

This gives us background to appreciate a fascinating study published recently in The Journal of Trauma—Injury Infection & Critical Care offering evidence that ANS, specifically vagal, stimulation can prevent the loss of intestinal barrier function associated with traumatic brain injury. The authors state:

“Traumatic brain injury (TBI) causes gastrointestinal dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system. We hypothesize that vagal nerve stimulation prevents an increase in intestinal permeability after TBI.”

They subjected their study animals to TBI after a selected cohort had undergone electrical stimulation of the cervical vagus nerve. They subsequently measured intestinal permeability, tumor necrosis factor-α (an inflammatory cytokine) and, very interestingly, glial fibrillary acidic protein (GFAP) which is a marker of enteric glial activity. What did they find?

“TBI increased intestinal permeability compared with sham…Vagal stimulation prevented TBI-induced intestinal permeability. TBI animals had an increase in intestinal tumor necrosis factor-α 6 hours after injury compared with vagal stimulation + TB…intestinal GFAP was 18.0-fold higher at 4 hours compared with sham and 1.6-fold higher than TBI alone.”

This has profound and practical clinical implications:

“In a mouse model of TBI, vagal stimulation prevented TBI-induced intestinal permeability. Furthermore, vagal stimulation increased enteric glial activity and may represent the pathway for central nervous system regulation of intestinal permeability.”

A paper published last summer in the Journal of Neurogastroenterology and Motility offers one example of a sensory-based peripheral modality that has a therapeutic effect on these central processes, in this case electroacupuncture.

“We evaluated the effect of acupuncture in treating visceral hyperalgesia in an animal model.”

The authors applied either electroacupuncture (EA) or sham acupuncture at acupoint ST-36 to rats with prior neonatal maternal separation stress. The day after the acupuncture treatment they were subject to colorectal distension, comparing them for pain threshold and visceromotor response. They also measured serotonin and Fos expression by immunohistochemistry in the colon, brainstem and spinal cord.

“Rats in EA group had significantly higher pain threshold compared to those in sham acupuncture group…They also had lower visceromotor response as measured by electromyogram compared to those received sham acupuncture at all colorectal distension pressures.”

Electroacupuncture is one of a number of ways to simulate the brain through sensory pathways. In this study the authors concluded:

“Electro acupuncture attenuates visceral hyperlagesia through down-regulation of central serotonergic activities in the brain-gut axis.”

My heart goes out to these study animals, but we can accept the further evidence presented in another paper published recently in The Journal of Trauma—Injury Infection & Critical Care. In this study the authors demonstrated repair of the gut barrier through vagal stimulation after abnormal intestinal permeability induced by burn trauma:

“Severe injury can cause intestinal permeability through decreased expression of tight junction proteins, resulting in systemic inflammation. Activation of the parasympathetic nervous system after shock through vagal nerve stimulation is known to have potent anti-inflammatory effects…We postulated that vagal nerve stimulation improves intestinal barrier integrity after severe burn through an efferent signaling pathway, and is associated with improved expression and localization of the intestinal tight junction protein occludin.”

The authors subjected their animals to burn injury after vagal nerve stimulation for 10 minutes. A separate underwent abdominal vagotomy before vagal nerve stimulation and burn. Intestinal barrier injury, histology, and changes in occludin expression were then assessed. The results were striking…

“Cervical vagal nerve stimulation decreased burn-induced intestinal permeability to FITC-dextran, returning intestinal permeability to sham levels. Vagal nerve stimulation before burn also improved gut histology and prevented burn-induced changes in occludin protein expression and localization. Abdominal vagotomy abrogated the protective effects of cervical vagal nerve stimulation before burn, resulting in gut permeability, histology, and occludin protein expression similar to burn alone.”

Improving parasympathetic function in general and vagal function in particular is of paramount importance in the management of most chronic disorders. The authors conclude:

Vagal nerve stimulation performed before injury improves intestinal barrier integrity after severe burn through an efferent signaling pathway and is associated with improved tight junction protein expression.

Actual case management of brain-gut axis disorders merits an entire textbook, but this can be borne in mind: diet, supplements, medicines, etc. are not enough—good gut function requires good brain output and autonomic regulation. Clinicians actively treating these conditions who are interested in how we apply functional testing for GI inflammation, infection, gut permeability, allergy, ANS function, the brain and brain-gut axis, etc.; and the various therapies brought to bear on the findings; are welcome to contact Lapis Light for collegial conversation.

 

IBS aetiology is most likely multi-factorial involving biological, psychological and social factors. Visceral hyperalgesia (or hypersensitivity) and visceral hypervigilance, which could be mediated by peripheral, spinal, and/or central pathways, constitute key concepts in current research on pathophysiological mechanisms of visceral hyperalgesia. The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity. At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia. This review presents recent advances in research on the pathophysiology of visceral hyperalgesia in IBS, with a focus on the role of stress and anxiety in central and peripheral response to visceral pain stimuli. Together, these findings support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered in IBS. This may be attributable to affective disturbances, negative emotions in anticipation of or during visceral stimulation, and altered pain-related expectations and learning processes. Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions. At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms. Investigating afferent immune-to-brain communication in visceral hyperalgesia as a component of the sickness response constitutes a promising future research goal.

Metabolic syndrome promotes cognitive decline

More evidence that metabolic syndrome, and its root causal factor insulin resistance, are damaging to the brain and promote cognitive decline appears in a study just published in the journal Neurology. The authors set out to…

“…examine associations between metabolic syndrome (MetS) and its individual components with risk of cognitive decline on specific cognitive functions.”

The assessed 4,323 women and 2,764 men aged 65 and over for cognitive decline and metabolic syndrome (possessing at least 3 of 5 cardio-metabolic abnormalities: hypertension, high waist circumference, hypertriglyceridemia, low high-density lipoprotein [HDL] cholesterol, hyperglycemia). The risk evaluation was adjusted for a number of variables including the APOE4 genotype. What did their data show?

MetS at baseline was associated with an increased risk of cognitive decline on MMSE [Mini-Mental State Examination for global cognitive function]…. Among MetS components, hypertriglyceridemia and low HDL cholesterol were significantly associated with higher decline on MMSE; diabetes, but not elevated fasting glycemia, was significantly associated with higher decline on BVRT [Benton Visual Retention Test for visual working memory]and IST [Isaacs Set Test for verbal fluency].”

The practical message for clinicians and the public is that blood sugar and insulin regulation are critical factors for brain health. Management begins with diet and lifestyle factors including exercise and encompasses specific needs for supplementation as determined by reliable laboratory investigations that disclose individual genetic and epigenetic factors. The authors conclude:

MetS as a whole and several of its components had a negative impact on global cognitive decline and specific cognitive functions in older persons.

Vitamin D is an independent risk factor for multiple sclerosis

Yet more evidence for the importance of immune regulation by vitamin D is presented in a paper just published in the journal Neurology. This study investigates the association between vitamin D and central nervous system (CNS) demyelination, the pathological process by which the fatty conductive nerve ‘insulation’ is damaged in disorders like multiple sclerosis. The authors set out to…

“…examine whether past and recent sun exposure and vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] levels) are associated with risk of first demyelinating events (FDEs) and to evaluate the contribution of these factors to the latitudinal gradient in FDE incidence in Australia.”

Over a period of three years they compared 216 subjects aged 18–59 years with a FDE to 395 controls matched for age, sex, and study region who had no CNS demyelination. Besides self-reported sun exposure by life stage the gathered objective measures of skin type and sun related damage, along with vitamin D status. Not surprisingly…

Higher levels of past, recent, and accumulated leisure-time sun exposure were each associated with reduced risk of FDE… Higher actinic skin damage and higher serum vitamin D status were independently associated with decreased FDE risk. Differences in leisure-time sun exposure, serum 25(OH)D level, and skin type additively accounted for a 32.4% increase in FDE incidence from the low to high latitude regions.”

There was a 93% decrease in first demyelinating events for every 10 nmol/L increase in serum 25(OH)D). The authors conclude:

Sun exposure and vitamin D status may have independent roles in the risk of CNS demyelination. Both will need to be evaluated in clinical trials for multiple sclerosis prevention.”

Elimination diet relieves ADHD, IgG blood tests are not helpful

A study just published in the prestigious medical journal The Lancet finds a clear relationship between diet and behavior in ADHD when investigated by a supervised elimination diet but not by IgG (immunoglobulin G antibody) blood tests. The authors state:

“The effects of a restricted elimination diet in children with attention-deficit hyperactivity disorder (ADHD) have mainly been investigated in selected subgroups of patients. We aimed to investigate whether there is a connection between diet and behaviour in an unselected group of children.”

They conducted a randomised controlled trial in which children aged 4-8 years who were diagnosed with ADHD were randomly assigned to either a 5 week restricted elimination diet or instructions for a healthy diet in the first phase.

“Thereafter, the clinical responders (those with an improvement of at least 40% on the ADHD rating scale [ARS]) from the diet group proceeded with a 4-week double-blind crossover food challenge phase (second phase), in which high-IgG or low-IgG foods (classified on the basis of every child’s individual IgG blood test results) were added to the diet.”

Pediatricians and others involved were masked to group and challenge allocation. Changes in the ARS score in both phases and correlations between food-specific IgG levels related and behavior were the endpoints. What did their data show?

“Between baseline and the end of the first phase, the difference between the diet group and the control group in the mean ARS total score was 23·7 according to the masked ratings… The ARS total score increased in clinical responders after the challenge by 20·8… In the challenge phase, after challenges with either high-IgG or low-IgG foods, relapse of ADHD symptoms occurred in 19 of 30 (63%) children, independent of the IgG blood levels.

This significant study offers three very important points here for clinicians and parents:

  1. Foods can trigger ADHD behavior.
  2. Supervised elimination diets can identify the offending foods.
  3. IgG blood tests do not identify them.

Parents and practitioners should appreciate the authors’ conclusion:

A strictly supervised restricted elimination diet is a valuable instrument to assess whether ADHD is induced by food. The prescription of diets on the basis of IgG blood tests should be discouraged.

Vitamin C sometimes indicated to lower homocysteine

As a practicing clinician (or knowledgeable layperson) have you encountered patients who continue to have higher plasma homocysteine levels than you’d like despite objective laboratory evidence (such as the relevant organic acids) that they are replete for vitamin B12, folic acid and vitamin B6? (I have.) A paper just published in the Annals of Nutrition & Metabolism throws some welcome light on the matter. The authors state:

“The factors influencing total plasma homocysteine levels (tHcy) are of special interest in the attempt to reduce cardiovascular risk…This investigation aimed to assess the independent effects of antioxidant vitamins on tHcy in elderly people.”

The authors examined 184 subjects in an aging population in Giessen (GISELA), Germany for the effects of plasma levels, intake and supplementation of vitamin C, vitamin E, and β-carotene on tHcy. What did their data show?

“Serum folate, the estimated glomerular filtration rate (eGFR), and plasma vitamin C showed a negative association with tHcy in simple regression analysis. In a subsequent multiple regression analysis, eGFR, serum folate, and plasma vitamin C were the relevant independent predictors of tHcy.”

In other words, higher plasma vitamin C was associated with lower homocysteine (along with the already recognized folic acid and eGFR as a metric for kidney function). There is good evidence for the importance of homocysteine in brain as well as cardiovascular health. The authors’ conclusion can be brought to mind when homocysteine levels fail to reach optimum despite the well-known interventions:

Vitamin C may be an independent predictor of tHcy in free-living elderly people and, therefore, should be considered in attempts to reduce tHcy.